182 related articles for article (PubMed ID: 38421887)
1. Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
Keller AL; Reiman LT; Perez de Acha O; Parzych SE; Forsberg PA; Kim PS; Bisht K; Wang H; van de Velde H; Sherbenou DW
Cancer Res Commun; 2024 Mar; 4(3):757-764. PubMed ID: 38421887
[TBL] [Abstract][Full Text] [Related]
2. Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple Myeloma.
Grab AL; Kim PS; John L; Bisht K; Wang H; Baumann A; Van de Velde H; Sarkar I; Shome D; Reichert P; Manta C; Gryzik S; Reijmers RM; Weinhold N; Raab MS
Cells; 2024 May; 13(10):. PubMed ID: 38786100
[TBL] [Abstract][Full Text] [Related]
3. Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo.
Díez-Alonso L; Falgas A; Arroyo-Ródenas J; Romencín PA; Martínez A; Gómez-Rosel M; Blanco B; Jiménez-Reinoso A; Mayado A; Pérez-Pons A; Aguilar-Sopeña Ó; Ramírez-Fernández Á; Segura-Tudela A; Perez-Amill L; Tapia-Galisteo A; Domínguez-Alonso C; Rubio-Pérez L; Jara M; Solé F; Hangiu O; Almagro L; Albitre Á; Penela P; Sanz L; Anguita E; Valeri A; García-Ortiz A; Río P; Juan M; Martínez-López J; Roda-Navarro P; Martín-Antonio B; Orfao A; Menéndez P; Bueno C; Álvarez-Vallina L
Sci Transl Med; 2024 Feb; 16(734):eadg7962. PubMed ID: 38354229
[TBL] [Abstract][Full Text] [Related]
4. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands.
Díaz-Tejedor A; Rodríguez-Ubreva J; Ciudad L; Lorenzo-Mohamed M; González-Rodríguez M; Castellanos B; Sotolongo-Ravelo J; San-Segundo L; Corchete LA; González-Méndez L; Martín-Sánchez M; Mateos MV; Ocio EM; Garayoa M; Paíno T
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731936
[TBL] [Abstract][Full Text] [Related]
5. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
6. Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma.
Roders N; Nakid-Cordero C; Raineri F; Fayon M; Abecassis A; Choisy C; Nelson E; Maillard C; Garrick D; Talbot A; Fermand JP; Arnulf B; Bories JC
Cancer Immunol Res; 2024 Apr; 12(4):478-490. PubMed ID: 38289260
[TBL] [Abstract][Full Text] [Related]
7. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023-A Podcast.
Costa LJ; Rodriguez-Otero P
Adv Ther; 2024 Apr; ():. PubMed ID: 38642197
[TBL] [Abstract][Full Text] [Related]
8. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
9. Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma.
Abrams RE; Pierre K; El-Murr N; Seung E; Wu L; Luna E; Mehta R; Li J; Larabi K; Ahmed M; Pelekanou V; Yang ZY; van de Velde H; Stamatelos SK
Sci Rep; 2022 Jun; 12(1):10976. PubMed ID: 35768621
[TBL] [Abstract][Full Text] [Related]
10. Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma.
Pouleau B; Estoppey C; Suere P; Nallet E; Laurendon A; Monney T; Pais Ferreira D; Drake A; Carretero-Iglesia L; Macoin J; Berret J; Pihlgren M; Doucey MA; Gudi GS; Menon V; Udupa V; Maiti A; Borthakur G; Srivastava A; Blein S; Mbow ML; Matthes T; Kaya Z; Edwards CM; Edwards JR; Menoret E; Kervoëlen C; Pellat-Deceunynck C; Moreau P; Zhukovsky E; Perro M; Chimen M
Blood; 2023 Jul; 142(3):260-273. PubMed ID: 37192303
[TBL] [Abstract][Full Text] [Related]
11. Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.
De Novellis D; Fontana R; Giudice V; Serio B; Selleri C
Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614086
[TBL] [Abstract][Full Text] [Related]
12. A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma.
Mei H; Li C; Jiang H; Zhao X; Huang Z; Jin D; Guo T; Kou H; Liu L; Tang L; Yin P; Wang Z; Ai L; Ke S; Xia Y; Deng J; Chen L; Cai L; Sun C; Xia L; Hua G; Hu Y
J Hematol Oncol; 2021 Oct; 14(1):161. PubMed ID: 34627333
[TBL] [Abstract][Full Text] [Related]
13. CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
Perez de Acha O; Reiman L; Jayabalan DS; Walker ZJ; Bosma G; Keller AL; Parzych SE; Abbott D; Idler BM; Ribadeneyra D; Niesvizky R; Forsberg PA; Mark TM; Sherbenou DW
Blood Adv; 2023 Nov; 7(21):6430-6440. PubMed ID: 37648670
[TBL] [Abstract][Full Text] [Related]
14. Ex vivo efficacy of BCMA-bispecific antibody TNB-383B in relapsed/refractory multiple myeloma.
Foureau DM; Bhutani M; Robinson M; Guo F; Pham D; Buelow B; Steuerwald N; Rigby K; Tjaden E; Leonidas M; Paul BA; Atrash S; Ndiaye A; Symanowski JT; Voorhees PM; Usmani SZ
EJHaem; 2020 Jul; 1(1):113-121. PubMed ID: 35847733
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors.
Metelo AM; Jozwik A; Luong LA; Dominey-Foy D; Graham C; Attwood C; Inam S; Dunlop A; Sanchez K; Cuthill K; Rice C; Streetly M; Bentley T; Boldajipour B; Sommer C; Sasu B; Benjamin R
Cancer Res Commun; 2022 Mar; 2(3):158-171. PubMed ID: 36874402
[TBL] [Abstract][Full Text] [Related]
16. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Sherbenou DW; Su Y; Behrens CR; Aftab BT; Perez de Acha O; Murnane M; Bearrows SC; Hann BC; Wolf JL; Martin TG; Liu B
Clin Cancer Res; 2020 Nov; 26(22):6028-6038. PubMed ID: 32917735
[TBL] [Abstract][Full Text] [Related]
17. BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
Cho SF; Lin L; Xing L; Li Y; Yu T; Anderson KC; Tai YT
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32516895
[TBL] [Abstract][Full Text] [Related]
18. CD38 targeted treatment for multiple myeloma.
Jelínek T; Mihályová J; Hájek R
Vnitr Lek; 2018; 64(10):939-948. PubMed ID: 30590941
[TBL] [Abstract][Full Text] [Related]
19. CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma.
Chen X; Wong OK; Reiman L; Sherbenou DW; Post L
Mol Cancer Ther; 2024 Feb; 23(2):127-138. PubMed ID: 37816503
[TBL] [Abstract][Full Text] [Related]
20. Elranatamab vs. teclistamab: battle of the BCMA bispecifics in relapsed/refractory multiple myeloma.
Moore DC; Granger K; Hill H; Karabinos A; Davis JA
Expert Rev Hematol; 2024 Jun; 17(6):197-200. PubMed ID: 38717927
[No Abstract] [Full Text] [Related]
[Next] [New Search]
